The Genomic and Molecular Engineering (GME) Core of the DDRCC provides cutting-edge technologies for the analysis and manipulation of the genetic material. These new technologies empower DDRCC members to pinpoint and characterize genetic factors that influence the development and course of digestive diseases and to dissect gene functions In important pathways relevant to digestive diseases. The GME is a new Core, restructured from the former Molecular Biology and Biochemistry Core. The GME Core divided into two components. The Genotype Analysis component offers sen/ices relating to the genetic analysis of patient samples. The services of the Genotype Analysis component Include (1) customized single nucleotide polymorphism (SNP) genotyping based on the Sequenom Massanray genotyping platfonn, (2) standard SNP genotyping panels for high-Interest genes, (3) ultra-high throughput DNA sequence analysis for genotyping, (4) other genotype analysis methods (such as TaqMan), (5) DNA preparation, and (6) statistical genetics support. The Genetic Engineering component offers services relating to the manipulation of genes in cellular and organismal model systems. The services ofthe Genetic Engineering component include (1) somatic cell genetic manipulation of genes using homologous recombination to knock in or knock out mutations, (2) recombineering technologies to manipulate large DNA segments in bacterial artificial chromosomes, (3) the construction of gene expression constructs using lentiviral vectors for ectopic expression or silencing of genes, (4) support for realtime PCR, and (5) support for the Odyssey image analysis system. The GME Core supports members for genotype analysis and genetic engineering experiments by supporting labor cost, providing discounts for reagents, and training members in new technologies. The Administrative Directors of the GME Core, Drs. Nathan Ellis and David Boone, oversee the operations of the respective components. Directors are responsible for ensuring proper scientific direction and efficient use of services and facilities of the component resources. Usage of the GME Core rapidly increased from start-up because of substantial cost savings, relevance, and high quality of services and resources, and it is anticipated usage will grow substantially during the next cycle of this Grant. Each of the Components offers training of new and established investigators unfamiliar with the supported experimental approaches. The GME Core has helped to foster multidisciplinary collaborations and promote productive exchanges brought about by sharing of resources

Public Health Relevance

The cutting-edge technological services provided by the Core facilitates the genetic analysis and characterization of genes that are important to the development and course of digestive diseases, including inflammatory bowel disease and colorectal cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK042086-22
Application #
8377910
Study Section
Special Emphasis Panel (ZDK1-GRB-8)
Project Start
Project End
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
22
Fiscal Year
2012
Total Cost
$203,023
Indirect Cost
$72,880
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Chen, Edmund B; Cason, Cori; Gilbert, Jack A et al. (2018) Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. J Gastrointest Surg 22:1112-1123
Chew, Justin; Leypunskiy, Eugene; Lin, Jenny et al. (2018) High protein copy number is required to suppress stochasticity in the cyanobacterial circadian clock. Nat Commun 9:3004
Ruderman, Sarah; Eshein, Adam; Valuckaite, Vesta et al. (2018) Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer. BMC Cancer 18:814
Dugas, Lara R; Lie, Louise; Plange-Rhule, Jacob et al. (2018) Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol. BMC Public Health 18:978
McIntosh, Christine M; Chen, Luqiu; Shaiber, Alon et al. (2018) Gut microbes contribute to variation in solid organ transplant outcomes in mice. Microbiome 6:96
Overstreet, A M; LaTorre, D L; Abernathy-Close, L et al. (2018) The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol 11:1454-1465
Panés, Julian; Vermeire, Séverine; Lindsay, James O et al. (2018) Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis 12:145-156
Feagan, Brian G; Schwartz, David; Danese, Silvio et al. (2018) Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis 12:621-626
Delmont, Tom O; Eren, A Murat (2018) Linking pangenomes and metagenomes: the Prochlorococcus metapangenome. PeerJ 6:e4320

Showing the most recent 10 out of 697 publications